Cas:1227-44-7 1,3-bis(4-methoxyphenyl)urea manufacturer & supplier

We serve Chemical Name:1,3-bis(4-methoxyphenyl)urea CAS:1227-44-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,3-bis(4-methoxyphenyl)urea

Chemical Name:1,3-bis(4-methoxyphenyl)urea
CAS.NO:1227-44-7
Synonyms:1,3-bis-(4-methoxyphenyl)urea
Molecular Formula:C15H16N2O3
Molecular Weight:272.29900
HS Code:2924299090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:342.5ºC at 760 mmHg
Density:1.249g/cm3
Index of Refraction:1.639
PSA:59.59000
Exact Mass:272.11600
LogP:3.49380

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,3-bis-(4-methoxyphenyl)urea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-bis-(4-methoxyphenyl)urea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-bis-(4-methoxyphenyl)urea Use and application,1,3-bis-(4-methoxyphenyl)urea technical grade,usp/ep/jp grade.


Related News: The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 1,3-bis(4-methoxyphenyl)urea manufacturer That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 1,3-bis(4-methoxyphenyl)urea supplier Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 1,3-bis(4-methoxyphenyl)urea vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 1,3-bis(4-methoxyphenyl)urea factory The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.